Mankind Pharma's Q2 profit rises 38-39% to about ₹711-716 crore; revenue up 17.3%

What happened

• Mankind Pharma reported revenue of ₹4,338 crore for the September 2026 quarter against ₹3,697 crore a year earlier, up 17.3%, Upstox said. Kotak Neo gave the same revenue figure and growth.
• Upstox put net profit at ₹711 crore against ₹512 crore, up 39%; Kotak Neo put it at ₹716 crore, up 37.7%. Both gave EBITDA as ₹1,175 crore, up 27.2%; Upstox gave the year-earlier figure as ₹924 crore, and both put the margin at 27.1% against 25%.
• Kotak Neo gave domestic revenue as ₹3,657 crore, up 14.8%, exports as ₹681 crore, up 32.7%, and consumer healthcare as ₹229 crore, up 1.2%. It listed growth of 18.7% in cardiac products, 15.8% in anti-diabetes and 19% in gastrointestinal, and said 50 products of the Bharat Serums and Vaccines business were on sale in the US.
• The shares closed at ₹2,312 against ₹2,212.60 on Friday on Kite data, a rise of 4.49% by my calculation, after a high of ₹2,333.90. Upstox's report is timed at 4:47 PM and Kotak Neo's at 5:33 PM.

Why it matters

Good to know: EBITDA margin is EBITDA as a share of revenue. A 27.1% margin means about ₹27 of operating profit before depreciation, interest and tax for every ₹100 of sales, up from about ₹25 a year earlier.

Key facts

Revenue

₹4,338 crore (₹3,697 crore a year earlier), up 17.3%

Net profit

₹711 crore, up 39%, per Upstox; ₹716 crore, up 37.7%, per Kotak Neo

EBITDA

₹1,175 crore, up 27.2%; margin 27.1% (25%)

Domestic / exports, per Kotak Neo

₹3,657 crore, up 14.8% / ₹681 crore, up 32.7%

Consumer healthcare, per Kotak Neo

₹229 crore, up 1.2%

Read the source

• Mankind Pharma Q2 results: Profit rises 39% YoY to ₹711 crore as operating margins improve 300 basis pointsUpstox
• Mankind Pharma Q2 FY 27 ResultsKotak Neo